Skip to main content

Table 3 Performance matrix of response model built on responders and non-responders then tested on stable disease patient samples

From: Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

 

Predicted

Responder

Predicted

Non-Responder

Indeterminate

Observed

Responder

17

1

8

Observed

Progressor

0

24

3

Observed

Stable Disease

4

6

3